Matthias Zehner

Dr. Matthias Zehner


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MZMatthias Zehner
Matthias Zehner
ACAchmet Imam Chasan
Achmet Imam Chasan
VSVerena Schuette
Verena Schuette
MEMaria Embgenbroich
Maria Embgenbroich
TQThomas Quast
Thomas Quast
SBSven Burgdorf
Sven Burgdorf
The molecular mechanisms regulating noncanonical protein transport across cellular membranes are poorly understood. Cross-presentation of exogenous antigens on MHC I molecules by dendritic cells (DCs) generally requires antigen translocation from the endosomal compartment into the cytosol for proteasomal degradation. In this study, we demonstrate that such translocation is controlled by the endocytic receptor and regulated by ubiquitination. Antigens internalized by the mannose receptor (MR), an endocytic receptor that targets its ligands specifically toward cross-presentation, were translocated into the cytosol only after attachment of a lysin48-linked polyubiquitin chain to the cytosolic region of the MR. Furthermore, we identify TSG101 as a central regulator of MR ubiquitination and antigen translocation. Importantly, we demonstrate that MR polyubiquitination mediates the recruitment of p97, a member of the ER-associated degradation machinery that provides the driving force for antigen translocation, toward the endosomal membrane, proving the central role of the endocytic receptor and its ubiquitination in antigen translocation.

29 July 2021 in Viruses
Verified
Journal Article
Open access
PDF file
SHSandro Halwe
Sandro Halwe
AKAlexandra Kupke
Alexandra Kupke
KVKanika Vanshylla
Kanika Vanshylla
FLFalk Liberta
Falk Liberta
HGHenning Gruell
Henning Gruell
SBStephan Becker
Stephan Becker
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.

14 November 2023 in Immunity
Verified
Journal Article
Closed access
MZMatthias Zehner
Matthias Zehner
MAMira Alt
Mira Alt
AAArtem Ashurov
Artem Ashurov
JGJory A. Goldsmith
Jory A. Goldsmith
RSRebecca Spies
Rebecca Spies
FKFlorian Klein
Florian Klein

24 August 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AUAlexander Uhrig
Alexander Uhrig
FPFrieder Pfäfflin
Frieder Pfäfflin
PTPinkus Tober-Lau
Pinkus Tober-Lau
VCVictor M. Corman
Victor M. Corman
MSMiriam S. Stegemann
Miriam S. Stegemann
LSLeif E. Sander
Leif E. Sander
Clinical data on Bundibugyo virus (BDBV) infection are limited, and no approved virus-specific treatment exists. We describe the case of a previously healthy 39-year-old healthcare worker who acquired BDBV infection while working in Ituri Province, Democratic Republic of the Congo (DRC), and was medically evacuated to Germany. He received MBP134, an investigational combination of two monoclonal antibodies, under an FDA Emergency Investigational New Drug (eIND) authorization, together with remdesivir and supportive care. Viral RNA concentrations were highest in oropharyngeal swabs and plasma, and became undetectable in blood, throat swabs, urine, and stool by day 13 after symptom onset and in semen by day 25. The patient’s serum demonstrated neutralizing activity against the current BDBV outbreak strain and other orthoebolaviruses. We detected BDBV-induced antibody responses not attributable to MBP134 or prior vaccination, providing evidence of endogenous humoral immunity following combined antiviral treatment. The patient recovered and was discharged on day 22 after symptom onset. This case report provides detailed insights into the clinical course, virologic dynamics and immune responses in BDBV infection during combined antiviral treatment, while larger clinical studies are needed to assess the efficacy and clinical utility of these therapeutic approaches.

24 August 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CGChristian Gaebler
Christian Gaebler
HLHan Ngoc Le
Han Ngoc Le
LMLuise Martin
Luise Martin
PTPaulina Tarnow
Paulina Tarnow
AGAlexander Gratopp
Alexander Gratopp
LSLeif Erik Sander
Leif Erik Sander
Five individuals from a single-family cluster, one rVSV-ZEBOV-vaccinated adult and four unvaccinated children aged 1–7 years, received investigational MBP134 as post-exposure prophylaxis (PEP) 5–6 days after high- to intermediate-risk occupational or household exposure to Bundibugyo ebolavirus (BDBV). MBP134 is a broadly neutralizing monoclonal antibody cocktail that has conferred protection against BDBV in non-human primates but to our knowledge has not previously been evaluated as PEP in humans. Given the absence of approved preventive interventions against BDBV and the substantial case fatality rate of Bundibugyo virus disease (BVD), MBP134 was administered as an individual treatment attempt under emergency Investigational New Drug (eIND) authorizations. Administration was well tolerated, with no treatment-related adverse events. Throughout the 21-day monitoring period, all family members remained free of clinical or laboratory evidence of BVD, as assessed by daily medical evaluation and serial PCR testing. Plasma Orthoebolavirus-reactive antibodies were detected after infusion, persisted throughout follow-up and mediated broad neutralizing activity against multiple Orthoebolavirus species, including authentic BDBV. Notably, endogenous BDBV-reactive IgM and IgA were detected in the adult following high-risk exposure despite persistently negative PCR results. Together, these findings support prospective evaluation of MBP134 as PEP for high-risk adult and pediatric contacts during BDBV outbreaks.

9 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMichael Korenkov
Michael Korenkov
MZMatthias Zehner
Matthias Zehner
HCHadas Cohen-Dvashi
Hadas Cohen-Dvashi
ABAliza Borenstein-Katz
Aliza Borenstein-Katz
LKLisa Kottege
Lisa Kottege
FKFlorian Klein
Florian Klein
SUMMARY: Somatic hypermutation (SHM) drives affinity maturation and continues over months in SARS-CoV-2 neutralizing antibodies. Yet, several potent SARS-CoV-2 antibodies carry no or only few mutations, leaving the question of how ongoing SHM affects neutralization. Here, we reverted variable region mutations of 92 antibodies and tested their impact on SARS-CoV-2 binding and neutralization. Reverting higher numbers of mutations correlated with decreasing antibody functionality. However, some antibodies, including the public clonotype VH1-58, remained unaffected for Wu01 activity. Moreover, while mutations were dispensable for Wu01-induced VH1-58 antibodies to neutralize Alpha, Beta, and Delta variants, they were critical to neutralize Omicron BA.1/BA.2. Notably, we exploited this knowledge to convert the clinical antibody tixagevimab into a BA.1/BA.2-neutralizer. These findings substantially broaden our understanding of SHM as a mechanism that not only improves antibody responses during affinity maturation, but also counteracts antigenic imprinting through antibody diversification and thus increases the chances of neutralizing viral escape variants.